Where We Stand
The Colon Cancer Alliance supports legislation that increases access to screening, removes barriers to quality treatment, lessens the financial burden on patients and expands research funding and clinical trial access. We’ve backed bills that address issues such as Medicare coverage for screening methods, limiting out-of-pocket costs for certain drugs and closing the “colonoscopy loophole” that left patients susceptible to unexpected costs after a colonoscopy. Our advocacy efforts are always driven by our mission of championing prevention, funding cutting-edge research and providing the highest quality patient support services.
Issues We’re Involved With
The Colon Cancer Alliance helps nearly one million individuals affected by colon cancer each year and wants its patients to have access to the best treatment options available. However, cancer treatment costs are increasingly burdensome. The median price for cancer treatment today is around $10,000 per month. The out-of-pocket costs for patients are also escalating. That said, should managed care and medical providers make decisions for patients based solely on what they think a patient can afford?
This is how CMS (Medicare) reimburses for outpatient chemo. The physician is reimbursed for the Average Sales Price (ASP) of the chemotherapy plus 6% to cover the cost, but this may be lowered to 4% or lower to save money. Lowering the reimbursement will discourage oncologist’s offices from taking new Medicare patients.
Medicare 340B is how indigent care is supposed to be funded. Pharma has to sell drugs at a steep discount to qualified hospitals (known as Disproportionate Share Hospitals or DSH). DSH sell these drugs at normal prices. The profit is supposed to cover indigent care. The concern is that hospitals are using it to pay the bottom line.
This is the equivalent term for generic but with biologic as opposed to chemical medicines. The issue is that biologics are way more complex. Aspirin is chemically all the same. Biologics aren’t. Little changes in manufacturing can make big differences. Think $100 bottle of wine vs. $5 wine. They’re both fermented grapes, right? But it can be done. We want biologics that are safe and affordable.